Cantargia - Nidanilimab transitioning to Phase IIa

Edison Investment Research - Pharmaceuticals & healthcare - Cantargia: On 7 December 2018 Cantargia reached an important milestone - the completion of the Phase I part of its Phase I/IIa CANFOUR study with nidanilimab in solid tumours. Patients are now being screened for the Phase IIa part of the study and we expect the first patient to be recruited in the coming weeks, with top-line data expected in early 2020. Cantargia also recently presented fresh pre-clinical data at an antibody conference that support the rationale for developing nidanilimab in combination with chemotherapy. Our valuation has increased to SEK2.28bn or SEK34.5/share reflecting the increased probability of success for nidanilimab.

ISIN: SE0006371126

Den vollständigen Artikel lesen ...